Benjamin Avi Derman MD
Hematologic Oncology
Assistant Professor at the University of Chicago
Join to View Full Profile
5758 S. Maryland Ave.Chicago, IL 60637
Dr. Derman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of ChicagoFellowship, Hematology and Medical Oncology, 2017 - 2020
Rush University Medical CenterChief Residency, Internal Medicine, 2016 - 2017- Rush University Medical CenterResidency, Internal Medicine, 2013 - 2016
Northwestern University The Feinberg School of MedicineClass of 2013
Certifications & Licensure
IL State Medical License 2013 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma Start of enrollment: 2023 May 30
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 5 citationsReal-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review.Benjamin Derman, Carlyn Tan, Ian Steinfield, Florence R Wilson, Dee Lin
Cancers. 2025-04-05 - 3 citationsBrain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma.Tyra K Grischke, Jennifer H Cooperrider, Anna Pula, Abigail Sneider, Samuel Yates
Blood Cancer Journal. 2025-03-28 - 28 citationsInternational myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.Luciano J Costa, Rahul Banerjee, Hira Mian, Katja Weisel, Susan Bal
Leukemia. 2025-03-01
Press Mentions
Oral Presentation at ASH 2025 Shows Canopy RTM Cuts Infection-Related Hospitalizations by 52% and Generates Nearly $1M in Annual Savings Per 1,000 PatientsDecember 9th, 2025- Means to an Endpoint: Measurable Residual Disease as a Regulatory Endpoint in Multiple MyelomaAugust 21st, 2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
